Partner Content Partner Content Updates on Antibiotic Drug Resistance the medical industry n... New updates on AMR presented at Superbugs USA 2017
News Novartis joins with Berkeley to tackle "undruggable" targets Project will focus on areas such as cancer and infectious diseases
Views & Analysis The Simulated Cell: can a digital model aid cancer drug disc... Can a simulated cell hold the key to sky-high attrition rates between cancer drug discovery and approval?
News UK drug discovery evolving - and facing up to Brexit A new UK report confirms the shift in pharma R&D spending from in-house teams to greater use of outsourcing and in-licensing - but also warns that investment in drug discovery in the co
News Stanford and twoXAR strike deal to take on liver cancer Stanford University School of Medicine is to take on liver cancer by teaming with twoXAR to develop new drug candidates.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.